25.87 USD
↗ 1.20 (4.86%)AT CLOSE (11:59 AM EDT)
Zenas BioPharma, Inc. Common Stock
ZBIONASDAQ • USD
26.66
↗ 0.79 (3.05%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
26.66
↗ 0.79 (3.05%)
Market: CLOSED
Zenas BioPharma, Inc. Common Stock (ZBIO) trades at $25.87 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. ZBIO is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Jun 26, 2026.
Open?$24.26
High?$26.00
Low?$23.90
Prev. Close?$24.67
Volume?3.5M
Avg. Volume?772.3K
VWAP?$24.94
Rel. Volume?4.53x
Bid / Ask
Bid?$25.95 × 200
Ask?$27.27 × 100
Spread?$1.32
Midpoint?$26.61
Valuation & Ratios
Market Cap?1.6B
Shares Out?63.1M
Float?22.7M
Float %?39.5%
P/E Ratio?N/A
P/B Ratio?4.86
EPS?-$6.73
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Employees
167
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2024-09-13
Address
852 WINTER STREET, SUITE 250
WALTHAM, MA 02451
Phone: 857-271-2954
WALTHAM, MA 02451
Phone: 857-271-2954
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?3
Momentum?50
Short Sent.?30
Piotroski F-Score?0/9Weak
Altman Z-Score?0.00Distress
Confidence?54%Low
Short InterestSqueeze Risk
Short % of Float?49.15%Squeeze Risk
Short Interest?11.1M
Days to Cover?19.3
Free Float22.7M
Avg Daily Volume575.8K
Settlement Date2026-06-15
Financial Health
Current Ratio?11.94Strong
Quick Ratio?11.94Strong
Cash Ratio?8.18Strong
Debt/Equity?0.79Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?4.86FAIR▾
Peers100
S&P38
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-126.6%WEAK▾
S&P3
ROA?-56.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-210480000
Enterprise Value?$1.4B
Fundamentals ratios updated end of day